Files

Download

Download Full Text (176 KB)

Program

Psychiatry

Training Level

Resident PGY 1

Institution

Henry Ford Hospital

Abstract

Objective: Clinicians have access to a variety of formulations of methylphenidate and amphetamine to treat attention-deficit hyperactivity disorder (ADHD). However, due to new emerging formulations clinicians may lack up-to-date knowledge about all available stimulant formulations. We present a comprehensive guide of 13 formulations of methylphenidate and 10 formulations of amphetamine that have U.S. Food and Drug Administration (FDA) approval to treat ADHD. Methods: A systematic review was completed through PUBMED using the following MeSH terms: “attention-deficit hyperactivity disorder”, “ADHD”, “stimulant”, “amphetamine”, and “methylphenidate”. Conclusions: Each formulation has a unique pharmacokinetic profile. Clinically, one formulation may not be suitable for all patients. This review should provide clinical guidance to help clinicians prescribe the most suitable treatment for an individual.

Publication Date

5-2019

Stimulant formulations for the treatment of ADHD

Share

COinS